Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine

Leukemia Research

Volumn 21, Issue 2, 1997, Pages 133-138

  Ruutu, Tapani ^a   Hänninen, Auli ^b   Järventie, Greta ^c   Koistinen, Pirjo ^d   Koivunen, Elli ^c   Kätkä, Kalevi ^c   Nousiainen, Tapio ^b   Oksanen, Kalevi ^e   Pelliniemi, Tarja Terttu ^f   Remes, Kari ^f   Timonen, Timo ^d   Volin, Liisa ^a   Elonen, Erkki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e KANTA HÄME CENTRAL HOSPITAL   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemotherapy; Cytarabine; Idarubicin; Myelodysplastic syndromes; Prognosis; Secondary acute leukemia

Indexed keywords

CYTARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SEPSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IDARUBICIN; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 0031080131     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(96)00116-6     Document Type: Article

References (25)

1. 1. Hamblin T. J. (1992) Intensive chemotherapy in myelodysplastic syndromes. Blood Rev. 6, 215.
2. 2. Sanz G. F. & Sanz M. A. (1992) Prognostic factors in myelodysplastic syndromes. Leukemia Res. 16, 77.
3. 3. Fenaux P., Preudhomme C. & Hebbar M. (1992) The role of intensive chemotherapy in myelodysplastic syndromes. Leukemia and Lymphoma 8, 43.
4. 4. De Witte T., Suciu S., Peetermans M., Fenaux P., Strijckmans P., Hayat M., Jaksic B., Selleslag D., Zittoun R., Dardenne M., Solbu G., Zwierzina H. & Muus P. (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months' duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9, 1805.
5. 5. Löffler H., Schmitz N. & Gassmann W. (1992) Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Hematol Oncol. Clin. N. Am. 6, 619.
6. 6. Speth P. A. J., Minderman H. & Haanen C. (1989) Idarubicin vs. daunorubicin: preclinical and clinical pharmacokinetic studies. Semin. Oncol. 16, 2, 2.
7. 7. Robert J. (1993) Clinical pharmacokinetics of idarubicin. Clin. Pharmacokinetics 24, 275.
8. 8. Fukushima T., Kawai Y., Urasaki Y., Yoshida A., Ueda T. & Nakamura T. (1994) Influence of idarubicinol on the antileukemic effect of idarubicin. Leukemia Res. 18, 943.
9. 9. Berman E. & McBride M. (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79, 3267.
10. 10. Minderman H., Linssen P., van der Lely N., Wessels J., Boezman J., De Witte T. & Haanen C. (1994) Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia 8, 382.
11. 11. Ganzina F., Pacciarini M. A. & Di Pietro N. (1986) Idarubicin (4-demethoxydaunorubicin): a preliminary overview of preclinical and clinical studies. Invest. New Drugs 4, 85.
12. 12. Christoffersen P. S., Rasmussen K. K. & Hermansen K. (1988) Cardiovascular effects of doxorubicin (adriamycin) and 4-demethoxydaunorubicin (idarubicin) in the conscious rat. Pharmac. Toxic. 62, 54.
13. 13. Berman E., Heller G., Santorsa J. A., McKenzie S., Gee T., Kempin S., Gulati S., Andreeff M., Kolitz J., Gabrilove J., Reich L., Mayer K., Keefe D., Trainor K., Schluger A., Penenberg D., Raymond V., O'Reilly R., Jhanwar S., Young C. & Clarkson B. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77, 1666.
14. 14. Mandelli F., Petti M. C., Ardia A., Di Pietro N., Di Raimondo F., Ganzina F., Falconi E., Geraci E., Ladogana S., Latagliata R., Malleo C., Nobile F., Petti N., Rotoli B., Specchia G., Tabilio A. & Resegotti L. (1991) A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute nonlymphoid leukemia. Euro. J. Cancer 27, 750.
15. 15. Vogler W. R., Velez-Garcia E., Weiner R. S., Flaum M. A., Bartolucci A. A., Omura G. A., Gerber M. C. & Banks P. L. C. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J. Clin. Oncol. 10, 1103.
16. 16. Wiernik P. H., Banks P. L. C., Case D. C., Arlin Z. A., Periman P. O., Todd M. B., Ritch P. S., Enck R. E. & Weitberg A. B. (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79, 313.
17. 17. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. & Sultan C. (1982) Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51, 189.
18. 18. Miller A. B., Hoogstraten B., Staquet M. & Winkler A. (1981) Reporting results of cancer treatment. Cancer 47, 207.
19. 19. Kaplan E. S. & Meier P. (1958) Non-parametric estimation from incomplete observations. Am. Stat. Ass. J. 53, 457.
20. 20. Estey E., Pierce S., Kantarjian H., O'Brien S., Beran M., Andreeff M., Escudier S., Koller C., Kornblau S., Robertson L. & Keating M. (1993) Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leukemia and Lymphoma 11, 2, 59.
21. 21. Lambertenghi Deliliers G., Annaloro C., Oriani A., Pozzoli E., Cortelezzi A., Cortellaro M., Mozzana R., Della Volpe A., Soligo D., Cofrancesco E., Boschetti C. & Polli E. E. (1993) Idarubicin in the therapy of acute myeloid leukemia: Final analysis in 57 previously untreated patients. Semin. Oncol. 20, 8, 27.
22. 22. De Witte T. (1994) New treatment approaches for myelodysplastic syndrome and secondary leukaemias. Ann. Oncol. 5, 401.
23. 23. Anderson J. E., Appelbaum F. R., Fisher L. D., Schoch G., Shulman H., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Doney K., Martin P. J., Sanders J. E., Sullivan K. M., Thomas E. D., Witherspoon R. P., Hansen J. A. & Storb R. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82, 677.
24. 24. De Witte T. & Gratwohl A. (1993) Bone marrow transplantation for myelodysplastic syndrome and secondary leukaemias. Br. J. Haematol. 84, 361.
25. 25. Ganser A. & Hoelzer D. (1992) Clinical course of myelodysplastic syndromes. Hematol. Oncol. Clin. N. Am. 6, 607.